TY - JOUR
T1 - Cortical spreading depression (CSD)-induced tolerance to transient focal cerebral ischemia in halothane anesthetized rats is affected by anesthetic level but not ATP-sensitive potassium channels
AU - Horiguchi, Takashi
AU - Kis, Bela
AU - Rajapakse, Nishadi
AU - Shimizu, Katsuyoshi
AU - Busija, David W.
N1 - Funding Information:
We thank Nancy Busija, MA, for aid in the editing of the manuscript. This work was supported by Grants HL30260, HL46558, HL50587, and HL77731 from the National Institute of Health and AHA Bugher Foundation Award 0270114N.
PY - 2005/11/16
Y1 - 2005/11/16
N2 - We investigated the participation of ATP-sensitive potassium (K ATP) channels, adenosine A1 receptors, and the effects of different levels of halothane anesthesia in the development of CSD-induced ischemic tolerance. To elicit CSD, 0.5 M KCl was applied for 2 h to the right hemisphere of halothane anesthetized male Wistar rats. The inhalation concentration of halothane during CSD was maintained at 0.5% (n = 8), 1.0% (n = 8), or 2.0% (n = 8). For control animals, saline was applied instead of KCl (n = 8). To inhibit KATP channels or adenosine A1 receptors, glibenclamide (0.1 mg/kg icv; n = 8), 5-hydroxydeconaoate (5-HD; 100 mg/kg ip; n = 12), or 8-Cyclopentyl-1, 3-dipropylxanthine (DPCPX) (1.0 mg/kg ip; n = 8) was applied before preconditioning during 1.0% halothane anesthesia. Temporary occlusion (120 min) of the right middle cerebral artery was induced 4 days after preconditioning and the infarct volume was measured. Preconditioning elicited under 1.0% halothane reduced cortical infarct volume from 277 ± 15 mm3 in the control group to 159 ± 14 mm3 in the CSD group (mean ± SEM, P < 0.05). In contrast, CSD induced during inhalation of 0.5% or 2.0% halothane did not confer ischemic tolerance. The reduction in infarct area with CSD during inhalation of 1% halothane was not changed in animals treated with glibenclamide or 5-HD or DPCPX. These results uncover a crucial role of halothane level but not of KATP channels or adenosine A1 receptors in the preconditioning effects of CSD.
AB - We investigated the participation of ATP-sensitive potassium (K ATP) channels, adenosine A1 receptors, and the effects of different levels of halothane anesthesia in the development of CSD-induced ischemic tolerance. To elicit CSD, 0.5 M KCl was applied for 2 h to the right hemisphere of halothane anesthetized male Wistar rats. The inhalation concentration of halothane during CSD was maintained at 0.5% (n = 8), 1.0% (n = 8), or 2.0% (n = 8). For control animals, saline was applied instead of KCl (n = 8). To inhibit KATP channels or adenosine A1 receptors, glibenclamide (0.1 mg/kg icv; n = 8), 5-hydroxydeconaoate (5-HD; 100 mg/kg ip; n = 12), or 8-Cyclopentyl-1, 3-dipropylxanthine (DPCPX) (1.0 mg/kg ip; n = 8) was applied before preconditioning during 1.0% halothane anesthesia. Temporary occlusion (120 min) of the right middle cerebral artery was induced 4 days after preconditioning and the infarct volume was measured. Preconditioning elicited under 1.0% halothane reduced cortical infarct volume from 277 ± 15 mm3 in the control group to 159 ± 14 mm3 in the CSD group (mean ± SEM, P < 0.05). In contrast, CSD induced during inhalation of 0.5% or 2.0% halothane did not confer ischemic tolerance. The reduction in infarct area with CSD during inhalation of 1% halothane was not changed in animals treated with glibenclamide or 5-HD or DPCPX. These results uncover a crucial role of halothane level but not of KATP channels or adenosine A1 receptors in the preconditioning effects of CSD.
KW - ATP-sensitive potassium channel
KW - Adenosine receptor
KW - Cerebral cortex
KW - Nitric oxide
KW - Preconditioning
KW - Stroke
UR - http://www.scopus.com/inward/record.url?scp=27744505151&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=27744505151&partnerID=8YFLogxK
U2 - 10.1016/j.brainres.2005.09.010
DO - 10.1016/j.brainres.2005.09.010
M3 - Article
C2 - 16256083
AN - SCOPUS:27744505151
SN - 0006-8993
VL - 1062
SP - 127
EP - 133
JO - Molecular Brain Research
JF - Molecular Brain Research
IS - 1-2
ER -